Circulating tumor DNA (ctDNA)(liquid biopsies) can help monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response. Author Ben Ho Park, MD, PhD, of the Vanderbilt-Ingram Cancer Center discusses current evidence regarding use of liquid biopsies in management of cancer with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content: Liquid Biopsies for Cancer Applications of Liquid Biopsy for Surgical Patients With Cancer
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from JAMA Clinical Reviews
Idiopathic Normal Pressure Hydrocephalus: Diagnosis and Treatment
Rheumatoid Arthritis
An Overview of Postural Orthostatic Tachycardia Syndrome (POTS)
Medication Treatments for Alcohol Use Disorder
Get summaries like this every morning.
Free AI-powered recaps of JAMA Clinical Reviews and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.